Who founded Gelsana Therapeutics?

Gelsana Therapeutics was founded by Melissa Krebs.

Who are Gelsana Therapeutics's investors?

Gelsana Therapeutics's investors include Innosphere Ventures, Boulder Ventures, Colorado BioScience Association, MINES VENTURE, Plug and Play Ventures.

How much funding has Gelsana Therapeutics raised?

Gelsana Therapeutics has disclosed $4.4M raised across 1 round.

Where is Gelsana Therapeutics headquartered?

Gelsana Therapeutics is headquartered in Aurora, US.

Gelsana Therapeutics

Aurora, US · Delaware corporation · 5 known investors

Find your way into Gelsana Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Gelsana Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

GelSana Therapeutics develops zwitterionic polymer-based biomaterials for wound care, addressing excess sustained inflammation that impedes healing. Its first product, CleraFlex, is a shelf-stable wound dressing designed to reduce inflammation, repel bacteria, balance moisture, and provide a protective barrier.

Biotech Healthtech Medical Devices New Materials

Founders & leadership

Melissa KrebsCEO and Founder

Donald GreggChief Commercial OfficerDonald Gregg held senior commercial leadership roles at medical device and digital health companies including Medtronic, Smiths Medical, GHX, and Zynex Monitoring, where he managed global P&Ls exceeding $500M and led product commercialization, go-to-market strategy, and M&A integration across multiple markets.

Adam RockerDirector R&DAdam Rocker is Director of R&D at GelSana Therapeutics, where he leads development of zwitterionic hydrogel wound dressings. He has experience advancing hydrogel systems through preclinical and large-animal validation stages and has secured NIH and AFWERX funding for product development.

Vicki AbbasExecutive Director Clinical OperationsVicki Abbas brings over 25 years of clinical research experience, including expertise in surgical product development and management of Phase 1–3 clinical trials in the biotechnology and pharmaceutical sectors. She now serves as Executive Director of Clinical Operations at Gelsana Therapeutics.

Ania CamplinFractional CFO

Board

Mike FreemanBoard directorGeneral Partner at Innosphere Ventures

Diana VerrilliBoard directorGeneral Manager, Navista (a Cardinal Health company) at Oncology Ventures

Investors · 5

Innosphere Ventures✓ confirmed by Gelsana TherapeuticsBoulder

How we know: Innosphere Ventures's portfolio page · the company's own site · open dataset · 5k.vc investor directory · Not right? Tell us

Boulder Ventureslisted by Boulder VenturesBoulder · $1M – $4M

Colorado BioScience Associationlisted by Colorado BioScience Association

MINES VENTURElisted by MINES VENTUREGolden

Plug and Play Ventureslisted by Plug and Play VenturesSilicon Valley · $50K – $400K

How we know: open dataset · 5k.vc investor directory · plugandplaytechcenter.com · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$4.4M disclosed across 1 round · 2023

▶$4.4MraisedOct 2026 · 33 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Melissa KrebsExecutive Officer, Director
Mike FreemanDirector
Diana VerrilliDirector

Offering amount: $4.9M
Amount sold: $4.4M
First sale: Nov 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Sanara MedTechSanara MedTech is a medical technology company focused on wound care and related healthcare products. The page lists its board of directors and executive leadership.

OrganogenesisOrganogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.

Companies working in the same space as Gelsana Therapeutics.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$299.6K
U.S. Air ForceAir Force	Phase I	2023	$75K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Gelsana Therapeutics do?: GelSana Therapeutics develops zwitterionic polymer-based biomaterials for wound care, addressing excess sustained inflammation that impedes healing. Its first product, CleraFlex, is a shelf-stable wound dressing designed to reduce inflammation, repel bacteria, balance moisture, and provide a protective barrier.
Who founded Gelsana Therapeutics?: Gelsana Therapeutics was founded by Melissa Krebs.
Who are Gelsana Therapeutics's investors?: Gelsana Therapeutics's investors include Innosphere Ventures, Boulder Ventures, Colorado BioScience Association, MINES VENTURE, Plug and Play Ventures.
How much funding has Gelsana Therapeutics raised?: Gelsana Therapeutics has disclosed $4.4M raised across 1 round.
Where is Gelsana Therapeutics headquartered?: Gelsana Therapeutics is headquartered in Aurora, US.